Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

Heart rate reductions were significant among patients receiving treatment, highlighting the need for careful monitoring.
QTcF prolongation was documented in a portion of the subjects, suggesting potential cardiac implications.
Combining camizestrant with CDK4/6 inhibitors showed promising therapeutic outcomes, warranting further investigation.
The study sample consisted of women diagnosed with advanced breast cancer, emphasizing the relevance of findings.

We only have this paper's title and publication details.

Observational study reports heart rate and QTcF changes in women with ER+ HER2− advanced breast cancer, indicating safety concerns.

Time course of heart rate reductions and QTcF

No takes yet. Share an insight, caveat, or question.

Baird et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share